Belgium's UCB visited by drugs probe authorities
Source: Agencies |
July 19, 2013, Friday
|
Print Edition
Print Edition
Belgian drugmaker UCB has been visited by Chinese authorities as China widens investigations into bribery by drugmakers, following allegations against Britain's GlaxoSmithKline.
A spokesman for UCB said yesterday that officials were also investigating a number of other foreign drug companies with operations in the country. He did not identify them.
Chinese police have accused GSK of bribing officials and doctors to boost sales and raise the price of its medicines, marking a hardening stance against malpractice by multinationals operating in the country.
"They've been launching inspections with several pharma companies active in the country, both Chinese and foreign companies such as ours, and as part of the process our Shanghai office was visited by the agency in the last 48 hours," the UCB spokesman said.
The officials visiting the group's office were from the State Administration for Industry and Commerce and were seeking information on compliance, he said.
The SAIC is one of China's main three anti-trust regulators in charge of market supervision.
Its investigations often overlap with the country's top watchdog, the National Development and Reform Commission, which recently launched a pricing investigation into local and international drugmakers, including GSK, Merck and Estella's Pharma.
On Monday, Chinese police accused GSK of transferring up to 3 billion yuan (US$489 million) to 700 travel agencies and consultancies to facilitate bribes - an allegation GSK said it was deeply concerned about and which it called "shameful."
China's action against GSK, including the detention of four senior Chinese executives and a ban on a British executive leaving the country, has sent a chill through the pharmaceutical sector. There's widespread speculation that other multinational companies would be drawn into the corruption investigations.
A spokesman for UCB said yesterday that officials were also investigating a number of other foreign drug companies with operations in the country. He did not identify them.
Chinese police have accused GSK of bribing officials and doctors to boost sales and raise the price of its medicines, marking a hardening stance against malpractice by multinationals operating in the country.
"They've been launching inspections with several pharma companies active in the country, both Chinese and foreign companies such as ours, and as part of the process our Shanghai office was visited by the agency in the last 48 hours," the UCB spokesman said.
The officials visiting the group's office were from the State Administration for Industry and Commerce and were seeking information on compliance, he said.
The SAIC is one of China's main three anti-trust regulators in charge of market supervision.
Its investigations often overlap with the country's top watchdog, the National Development and Reform Commission, which recently launched a pricing investigation into local and international drugmakers, including GSK, Merck and Estella's Pharma.
On Monday, Chinese police accused GSK of transferring up to 3 billion yuan (US$489 million) to 700 travel agencies and consultancies to facilitate bribes - an allegation GSK said it was deeply concerned about and which it called "shameful."
China's action against GSK, including the detention of four senior Chinese executives and a ban on a British executive leaving the country, has sent a chill through the pharmaceutical sector. There's widespread speculation that other multinational companies would be drawn into the corruption investigations.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
